ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Meeting News

Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

Kara Nyberg, PhD
on: October 09, 2020In: Meeting News
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more


ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Kara Nyberg, PhD
on: October 09, 2020In: Meeting News
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more

Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy

Joy Curzio
on: October 09, 2020In: Meeting News
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy

In his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of […] Read more

FDA Perspectives on the Use of Liquid Biopsy in NSCLC

Kara Nyberg, PhD
on: October 09, 2020In: Industry News & Regulatory Approvals, Meeting News
FDA Perspectives on the Use of Liquid Biopsy in NSCLC

The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more

Biopsy Options Create New Decision-making Points for Clinicians

Kara Nyberg, PhD
on: October 09, 2020In: Meeting News
Biopsy Options Create New Decision-making Points for Clinicians

Understanding the differences in liquid biopsy approaches, as well as how they complement tissue, can be important to therapeutic selection and outcomes. Read more

The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma

Federica Grosso, MD
+more
on: September 29, 2020In: Meeting News
The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma

At this year’s American Society of Clinical Oncology Virtual Meeting, the final results of the RAMES study were presented.1 RAMES was a prospective, placebo-controlled, phase II, randomized study in which […] Read more

Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role

on: September 06, 2020In: Meeting News
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to
            Patient’s Role

By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States […] Read more

Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status

on: September 06, 2020In: Meeting News
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview
            of Promising Phase II Data, Phase III Status

By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases […] Read more

First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC

on: September 06, 2020In: Meeting News
First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC

By Kara Nyberg, PhD Adding sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. In the randomized, placebo-controlled, phase III […] Read more

Managing lung cancer in the time of COVID-19

on: August 14, 2020In: Meeting News
Managing lung cancer in the time of COVID-19

Register Now REGISTER NOW for the Medscape Education and IASLC Exclusive Webinar: Immunotherapy and the COVID-19 Pandemic: Addressing Clinical Case Challenges in Lung Cancer on Tuesday, August 11, 2020 @ […] Read more

«‹12131415161718›»
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy